Episode Player

On the Couch with Dr Liz Dallimore (Argenica): Phase Two, FDA and What's Ahead

On the Couch

Chapters
0:00
Welcome And Who Argenica Is
2:05
The Brain Injury Problem To Solve
7:50
Phase Two Stroke Data At ESOC
14:40
Why Neuroprotection Usually Fails
22:55
Subgroups Signals And The FDA Path
29:55
AI Imaging And The Broader Pipeline
37:05
Funding Partnerships And What Next
On the Couch
On the Couch with Dr Liz Dallimore (Argenica): Phase Two, FDA and What's Ahead
May 15, 2026
Marcus Today

In this episode of On the Couch, Henry Jennings speaks with Dr Liz Dallimore, CEO of Argenica Therapeutics (ASX: AGN).

Fresh from presenting phase two trial data at a major international stroke conference, Liz walks through what the results showed, why neuroprotection is such a difficult space, and what the path forward looks like for the company.

—

Marcus Today – Daily Market Insights

Marcus Today provides clear, practical commentary for self-directed investors – covering markets, portfolios, education, and decision-making without the noise.

If you'd like to go further:

Start a free 14-day trial of Marcus Today
http://bit.ly/mt-trial-podcast

Join Marcus Today
Use code MTPODCAST for 10% off
http://bit.ly/mt-join-podcast-offer

MT20 – Managed ETF Portfolio
A professionally managed portfolio run by Marcus Padley and the team, using ASX-listed ETFs with active market timing.
http://bit.ly/mt20-podcast

Principles – How We Think About Investing
A short video series on timing, behaviour, and decision-making. No stock tips.
http://bit.ly/mt-principles-podcast

—

Disclaimer
This podcast is general information only and does not consider your personal circumstances. It is not personal financial advice.